A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients with Advanced Solid Malignancies
Phase 1
- Conditions
- Advanced Solid Malignancies
- Registration Number
- JPRN-UMIN000008807
- Lead Sponsor
- Zenyaku Kogyo Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Have received any investigational agents within the 4 weeks prior to the start of dosing with ZSTK474; 2.Have previously been treated with a phosphatidylinositol 3 kinase (PI3K) inhibitor; 3.Have serious or significant intercurrent illnesses or underlying diseases, including, but not limited to: a.History of diabetes b.Hepatic c.Renal d.Cardiovascular e.Others 4.Patients who are participating in the other clinical study or at the time of informed consent of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method